Repligen Corp (RGEN)

149.90 +6.85 (+4.79%) USD  |  NASDAQ  |  Jan 03, 16:00
152.00 +2.10 (+1.40%) After-Hours: 04:19
More

Repligen Research and Development Expense (Annual): 42.72M for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for RGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
QuidelOrtho Corp 246.80M
West Pharmaceutical Services Inc 68.40M
Perspective Therapeutics Inc 21.31M
Xtant Medical Holdings Inc 1.336M
Catheter Precision Inc 0.475M